Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genotypic resistance profile in treatment-experienced HIV-infected individuals after abacavir and efavirenz salvage regimen.

Antiviral research - 1 Feb 2004

Vallejo Alejandro, Olivera Mercedes, Rubio Amalia, Sánchez-Quijano Armando, Lissen Eduardo, Leal Manuel

Abstract excerpt

Once highly active antiretroviral therapy (HAART) fails to suppress HIV replication and resistant viruses emerge, it is difficult to find a salvage regimen since cross-resistance is high among the available classes of antiretroviral drugs. In this retrospective analysis, genotypic resistance profiles were analysed in 24 patients who switched treatment to abacavir (ABV), efavirenz (EFV), and either a NRTI or a PI...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alkynes
Share to Antiretroviral Therapy, Highly Active

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Benzoxazines

Share to Cyclopropanes

Share to Dideoxynucleosides

Share to HIV Protease

Share to Oxazines

Share to Salvage Therapy

Source

Identifiers

PMID: 14670587
DOI: 10.1016/s0166-3542(03)00154-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genotypic resistance profile in treatment-experienced HIV-infected individuals after abacavir and efavirenz salvage regimen.PMID 14670587Read ↗

Clinical implications of genotypic resistance to the newer antiretroviral drugs in HIV-1-infected patients with virological failure.Semantic proximity Read ↗

Genotypic and phenotypic nevirapine resistance correlates with virological failure during salvage therapy including abacavir and nevirapine.Semantic proximity Read ↗

Cross-resistance patterns among HIV protease inhibitors.Semantic proximity Read ↗

Strategies for overcoming resistance in HIV-1 infected patients receiving HAART.Semantic proximity Read ↗

Impact of HIV type 1 drug resistance mutations and phenotypic resistance profile on virologic response to salvage therapy.Semantic proximity Read ↗

Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.Semantic proximity Read ↗

Phenotypic HIV-1 resistance correlates with treatment outcome of nelfinavir salvage therapy.Semantic proximity Read ↗

Salvage therapy with abacavir plus a non-nucleoside reverse transcriptase inhibitor and a protease inhibitor in heavily pre-treated HIV-1 infected patients. Swiss HIV Cohort Study.Semantic proximity Read ↗

Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome.Semantic proximity Read ↗

Salvage therapy with abacavir in HIV-1-infected patients with previously documented M184V mutation: a possibility of NRTI recycling.Semantic proximity Read ↗

Low genetic barrier to large increases in HIV-1 cross-resistance to protease inhibitors during salvage therapy.Semantic proximity Read ↗

A prospective comparison of the two main indications of efavirenz in 2001 highly active antiretroviral therapy (HAART) regimens: first-line versus salvage use.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.